Clinical Trial Update: Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety of rovalpituzumab tesirine for third-line and later relapsed/refractory small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• rovalpituzumab tesirine (rovalpituzumab tesirine)

Snippet

Sponsor: AbbVie | Conditions: Small Cell Lung Cancer | Phase 3 | Status: WITHDRAWN